Tetrazine 12.5 mg (Tetrabenazine) Tablets

Introduction:

Tetrazine 12.5 mg, manufactured by Beacon Pharmaceuticals Ltd and supplied by Orio Pharma, is a highly effective treatment used for managing movement disorders, including Huntington’s disease. Containing Tetrabenazine, Tetrazine 12.5 mg helps reduce involuntary muscle movements (chorea) associated with these disorders. It acts on chemicals in the brain that are linked to muscle movement, providing much-needed relief for patients suffering from debilitating movement disorders.

Manufacturing Excellence of Beacon Pharmaceuticals Ltd:

Beacon Pharmaceuticals Ltd. is known for producing top-quality pharmaceutical products that meet international standards. The development of Tetrazine 12.5 mg reflects Beacon’s commitment to advancing neurological treatments through thorough research, superior quality control, and best manufacturing practices. Their focus on patient safety and therapeutic efficacy ensures that Tetrazine 12.5 mg is a reliable option for managing movement disorders.

Mechanism of Action:

Tetrazine 12.5 mg contains Tetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor that works by decreasing the uptake of neurotransmitters like dopamine in nerve cells. By reducing dopamine levels, Tetrabenazine helps to control the involuntary movements characteristic of disorders like Huntington’s disease. This mechanism makes Tetrazine 12.5 mg an essential therapy for patients struggling with abnormal movements that interfere with daily life.

Clinical Applications:

Tetrazine 12.5 mg is indicated for the treatment of:

• Huntington’s Disease-Related Chorea: Tetrazine 12.5 mg is primarily used to manage chorea (involuntary jerky movements) associated with Huntington’s disease.
• Other Movement Disorders: It may also be used to treat other movement disorders as determined by a healthcare provider.

Clinical studies have demonstrated that Tetrabenazine effectively reduces chorea in patients with Huntington’s disease, improving their ability to perform daily activities and enhancing their quality of life.

Dosage and Administration:

The recommended starting dose of Tetrazine 12.5 mg is one tablet once or twice daily, with gradual adjustments based on the patient’s response to treatment. The dosage can be increased by 12.5 mg increments every three to four days, up to a maximum of 50 mg to 75 mg per day, depending on individual patient needs and tolerability. Patients should take Tetrazine 12.5 mg exactly as prescribed by their healthcare provider, and regular monitoring is essential to assess therapeutic effectiveness and manage any potential side effects.

Benefits of Tetrazine 12.5 mg:

• Effective Control of Chorea: Tetrazine 12.5 mg provides targeted relief from involuntary movements, helping patients regain control of their muscle function.
• Improved Quality of Life: By reducing the severity of involuntary movements, Tetrazine 12.5 mg improves the quality of life for patients with Huntington’s disease and other movement disorders.
• Well-Tolerated: Tetrazine 12.5 mg has been shown to be generally well-tolerated when used under proper medical supervision, with side effects that can be managed through regular monitoring.
• Flexible Dosing: The ability to adjust the dosage of Tetrazine 12.5 mg allows healthcare providers to tailor treatment to the individual needs of the patient, optimizing therapeutic outcomes.

Supplier: Orio Pharma

Orio Pharma ensures that Tetrazine 12.5 mg is readily available to healthcare providers and patients, offering reliable access to this critical treatment for movement disorders. Their commitment to efficient supply and distribution supports effective management of conditions like Huntington’s disease, improving patient outcomes.

Conclusion:

Tetrazine 12.5 mg (Tetrabenazine) by Beacon Pharmaceuticals Ltd, supplied by Orio Pharma, is an essential therapy for managing involuntary movements associated with Huntington’s disease and other movement disorders. This VMAT2 inhibitor offers a targeted approach to controlling symptoms, helping patients regain function and quality of life. By incorporating Tetrazine 12.5 mg into their treatment plans, healthcare providers can offer patients a reliable and effective solution for managing challenging neurological conditions.